S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Hagop M. Kantarjian,Moshe Talpaz,Susan O'Brien,Francis J. Giles,Guillermo Garcia-Manero,Stefan Faderl,Deborah A. Thomas,Jianqin Shan,Mary Beth Rios,Jorge E. Cortes +9 more
TL;DR: It is concluded that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.
Journal ArticleDOI
Resveratrol blocks interleukin-1β–induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells
Zeev Estrov,Shishir Shishodia,Stefan Faderl,David Harris,Quin Van,Hagop M. Kantarjian,Moshe Talpaz,Bharat B. Aggarwal +7 more
TL;DR: The data showing that resveratrol is an effective in vitro inhibitor of AML cells suggest that this compound may have a role in future therapies for AML.
Journal ArticleDOI
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Hagop M. Kantarjian,Varsha Gandhi,Jorge E. Cortes,Srdan Verstovsek,Min Du,Guillermo Garcia-Manero,Francis J. Giles,Stefan Faderl,Susan O'Brien,Sima Jeha,Jan Davis,Zeev Shaked,Adam R. Craig,Michael J. Keating,William Plunkett,Emil J. Freireich +15 more
TL;DR: Clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance.
Journal ArticleDOI
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop M. Kantarjian,Susan O'Brien,Elias J. Jabbour,Guillermo Garcia-Manero,Alfonso Quintás-Cardama,Jenny Shan,Mary Beth Rios,Farhad Ravandi,Stefan Faderl,Tapan M. Kadia,Gautam Borthakur,Xuelin Huang,Richard E. Champlin,Moshe Talpaz,Jorge E. Cortes +14 more
TL;DR: Survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML, and Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP -CML and accentuated theimpact of age in AP- and BP-C ML.
Journal ArticleDOI
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge E. Cortes,Moshe Talpaz,Susan O'Brien,Dan Jones,Rajyalakshmi Luthra,Jenny Shan,Francis J. Giles,Stefan Faderl,Srdan Verstovsek,Guillermo Garcia-Manero,Mary Beth Rios,Hagop M. Kantarjian +11 more
TL;DR: Achieving a major molecular response, particularly within the first year of therapy, is predictive of a durable cytogenetic remission and may be the future goal of therapy in CML.